Diffusion pharmaceuticals inc. (DFFN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating activities:
Net loss

-11,610

-11,799

-13,618

-17,533

-17,803

-18,369

-11,009

807

23,960

-1,364

-5,724

-16,258

-40,452

-18,036

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,065

-11,092

-14,216

-14,352

0

0

0

-

-

-

-

-

-

-

-

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

162

164

0

0

0

Depreciation

106

97

99

108

100

110

109

110

89

67

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18

14

8

-311

55

376

566

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

615

515

635

817

988

1,221

1,238

1,203

1,198

1,240

1,243

1,340

1,363

1,391

1,342

1,093

891

594

905

1,548

1,552

1,606

0

0

0

-

-

-

-

-

-

-

-

(Gain) / loss on adjustments to fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,980

0

0

0

-

-

-

-

(Gain)/loss on adjustment to fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Warrants, options and stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,726

3,643

0

0

0

Common stock issued for advisory services

-

-

-

-

-

-

-

-

-

-

-

-

-

1,409

1,409

1,409

487

0

0

0

0

-

-

-

-

-

-

-

0

-

-

-

-

Warrant related expense, change in fair value, and other financing expenses

-

-

-

-

-

-

-

-

-

8,976

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant related expense and change in fair value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in deferred income taxes

120

332

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-22

33

43

119

92

38

12

78

112

165

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Stock issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses, deposits and other assets

-200

-426

54

292

27

1

-403

410

657

664

393

-233

-316

-319

-14

20

141

29

-446

-526

-707

-979

-559

-511

-322

0

25

-11

29

-9

0

0

0

Accounts payable, accrued expenses and other liabilities

-138

567

161

164

211

-275

-301

-805

-776

-1,663

-914

-614

-929

991

526

703

1,310

647

-628

-472

-3,985

-3,801

-3,685

-4,106

255

130

-192

-216

-80

-401

0

0

0

Net cash used in operating activities

-10,705

-9,858

-10,447

-10,211

-10,140

-10,772

-10,027

-11,999

-12,205

-12,332

-11,464

-9,440

-9,553

-10,768

-11,620

-10,737

-8,876

-5,185

-4,849

-5,846

-9,536

-9,030

0

0

0

-

-

-

-

-4,310

0

0

0

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

447

438

64

6

2

28

31

40

40

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of certificates of deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash received in reverse merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

8,500

8,500

8,500

8,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-447

-10,438

-10,064

-6

8,498

8,471

8,468

8,460

2,459

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Cash flows provided by financing activities:
Proceeds received from the exercise of common stock warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of Series A convertible preferred stock and warrants, net

-

-

-

-

-

-

-

-

-

22,129

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of Series A convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Payments on notes payable to officers and a director

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,851

-3,483

0

0

0

Proceeds from the sale of common stock

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing costs that were previously classified in accounts payable

0

-

-

-

-

428

456

511

192

125

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

0

-

-

-

-

9,867

9,839

7,904

16,634

20,123

20,097

23,912

15,907

1,825

0

0

0

-

-

-

-

30,709

0

0

0

-

-

-

-

4,524

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Decrease in cash and equivalents from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Decrease in cash and equivalents from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net decrease in cash and cash equivalents

5,494

6,186

-4,878

-4,561

-10,865

-905

9,802

5,521

3,987

7,343

-1,805

4,407

6,346

-444

1,117

118

1,970

-339

-2,337

-4,704

23,220

21,628

23,532

27,060

110

-57

98

35

98

213

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Reclassification of deferred offering costs upon completion of private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series A cumulative preferred dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of subscription receivable upon sale of Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of deferred offering costs upon completion of private placement

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs in accounts payable and accrued expenses

0

-

-

0

0

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right of use asset and current and noncurrent liability

-

334

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of accrued dividends related to the issuance of common stock to Series A convertible preferred stock holders

-

-

-

-

-

1,148

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

206

414

0

0

0

Deferred salary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,145

1,152

0

0

0

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

663

559

0

0

0

Series A cumulative preferred dividends

-

-

-

-

-

85

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of convertible notes and related accrued interest into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

711

20,364

20,412

20,412

19,700

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Consideration in connection with RestorGenex Corporation merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

21,261

21,261

21,261

21,261

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of business in exchange for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,800

0

0

0

-

-

-

-

-

-

-

-

Cash paid during the period for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0